Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
UTHR UNITED THERAPEUTICS Corp
- Stocks
- Healthcare
- NASDAQ: UTHR
Price (delayed)
$282.61
Market cap
$12.75B
P/E Ratio
10.44
Dividend/share
N/A
EPS
$27.08
Enterprise value
$11.05B
United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and
Highlights
The debt has plunged by 67% YoY and by 33% from the previous quarter
The quick ratio has increased by 44% year-on-year and by 5% since the previous quarter
Key stats
What are the main financial stats of UTHR
Market
Valuations
Earnings
Shares outstanding
45.11M
Market cap
$12.75B
Enterprise value
$11.05B
Price to earnings (P/E)
10.44
Price to book (P/B)
1.86
Price to sales (P/S)
4.24
EV/EBIT
6.91
EV/EBITDA
6.59
EV/Sales
3.69
Revenue
$2.99B
Gross profit
$2.66B
Operating income
$1.4B
Net income
$1.21B
EBIT
$1.6B
EBITDA
$1.68B
Free cash flow
$1.13B
Per share
Balance sheet
Liquidity
EPS
$27.08
EPS diluted
$25.08
Free cash flow per share
$25.14
Book value per share
$151.57
Revenue per share
$66.68
TBVPS
$169.98
Total assets
$7.74B
Total liabilities
$936.7M
Debt
$200M
Equity
$6.81B
Working capital
$3.22B
Debt to equity
0.03
Current ratio
5.46
Quick ratio
5.05
Net debt/EBITDA
-1.01
Margins
Efficiency
Dividend
EBITDA margin
56%
Gross margin
89%
Net margin
40.4%
Operating margin
46.9%
Return on assets
16.7%
Return on equity
19.3%
Return on invested capital
31.6%
Return on capital employed
22.8%
Return on sales
53.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
UTHR stock price
How has the UNITED THERAPEUTICS stock price performed over time
Intraday
-0.52%
1 week
-2.8%
1 month
-10.24%
1 year
-10.83%
YTD
-19.9%
QTD
-8.32%
Financial performance
How have UNITED THERAPEUTICS's revenue and profit performed over time
Revenue
$2.99B
Gross profit
$2.66B
Operating income
$1.4B
Net income
$1.21B
Gross margin
89%
Net margin
40.4%
The company's gross profit rose by 20% YoY and by 3.8% QoQ
The company's revenue rose by 20% YoY and by 4.1% QoQ
UNITED THERAPEUTICS's net income has increased by 15% YoY
The operating income has grown by 12% YoY
Price vs fundamentals
How does UTHR's price correlate with its fundamentals
Growth
What is UNITED THERAPEUTICS's growth rate over time
Valuation
What is UNITED THERAPEUTICS stock price valuation
P/E
10.44
P/B
1.86
P/S
4.24
EV/EBIT
6.91
EV/EBITDA
6.59
EV/Sales
3.69
The stock's P/E is 25% below its 5-year quarterly average of 14.0 and 21% below its last 4 quarters average of 13.3
The company's EPS rose by 21% YoY and by 2.4% QoQ
The equity has increased by 28% year-on-year and by 6% since the previous quarter
UTHR's price to book (P/B) is 22% lower than its last 4 quarters average of 2.4 and 11% lower than its 5-year quarterly average of 2.1
The company's revenue rose by 20% YoY and by 4.1% QoQ
The stock's P/S is 20% below its last 4 quarters average of 5.3 and 15% below its 5-year quarterly average of 5.0
Efficiency
How efficient is UNITED THERAPEUTICS business performance
The ROIC has grown by 23% YoY
UNITED THERAPEUTICS's return on assets has increased by 8% YoY but it has decreased by 3.5% QoQ
The company's return on sales fell by 7% YoY and by 2.9% QoQ
The ROE has contracted by 4.9% from the previous quarter but it has grown by 3.2% YoY
Dividends
What is UTHR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for UTHR.
Financial health
How did UNITED THERAPEUTICS financials performed over time
The current ratio has grown by 45% YoY and by 4% from the previous quarter
The quick ratio has increased by 44% year-on-year and by 5% since the previous quarter
The debt is 97% less than the equity
UNITED THERAPEUTICS's debt to equity has shrunk by 73% YoY and by 40% QoQ
The debt has plunged by 67% YoY and by 33% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.